CN105130997A - 一种库潘尼西的制备方法 - Google Patents

一种库潘尼西的制备方法 Download PDF

Info

Publication number
CN105130997A
CN105130997A CN201510617987.6A CN201510617987A CN105130997A CN 105130997 A CN105130997 A CN 105130997A CN 201510617987 A CN201510617987 A CN 201510617987A CN 105130997 A CN105130997 A CN 105130997A
Authority
CN
China
Prior art keywords
pannixi
base
morpholine
amino
agent
Prior art date
Application number
CN201510617987.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN105130997B (zh
Inventor
许学农
Original Assignee
苏州明锐医药科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 苏州明锐医药科技有限公司 filed Critical 苏州明锐医药科技有限公司
Priority to CN201510617987.6A priority Critical patent/CN105130997B/zh
Publication of CN105130997A publication Critical patent/CN105130997A/zh
Application granted granted Critical
Publication of CN105130997B publication Critical patent/CN105130997B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
CN201510617987.6A 2015-09-25 2015-09-25 一种库潘尼西的制备方法 CN105130997B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510617987.6A CN105130997B (zh) 2015-09-25 2015-09-25 一种库潘尼西的制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510617987.6A CN105130997B (zh) 2015-09-25 2015-09-25 一种库潘尼西的制备方法

Publications (2)

Publication Number Publication Date
CN105130997A true CN105130997A (zh) 2015-12-09
CN105130997B CN105130997B (zh) 2017-12-05

Family

ID=54716624

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510617987.6A CN105130997B (zh) 2015-09-25 2015-09-25 一种库潘尼西的制备方法

Country Status (1)

Country Link
CN (1) CN105130997B (und)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017049983A1 (zh) * 2015-09-25 2017-03-30 苏州立新制药有限公司 库潘尼西的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1688582A (zh) * 2002-09-30 2005-10-26 拜尔药品公司 稠合吡咯－嘧啶衍生物
CN101631464A (zh) * 2006-12-05 2010-01-20 拜耳先灵医药股份有限公司 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1688582A (zh) * 2002-09-30 2005-10-26 拜尔药品公司 稠合吡咯－嘧啶衍生物
CN101631464A (zh) * 2006-12-05 2010-01-20 拜耳先灵医药股份有限公司 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C. BALAKUMAR，等: "Synthesis, anti-in flammatory evaluation and docking studies of some new fluorinated fused quinazolines", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 *
CESAR MENDOZA-MARTÍNEZ，等: "Antileishmanial activity of quinazolin e derivatives: Synthesis, docking screens, molecular dynamic simulations and electrochemical studies", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017049983A1 (zh) * 2015-09-25 2017-03-30 苏州立新制药有限公司 库潘尼西的制备方法

Also Published As

Publication number Publication date
CN105130997B (zh) 2017-12-05

Similar Documents

Publication Publication Date Title
US10138249B2 (en) Triazolopyridines and triazolopyrazines as LSD1 inhibitors
EP3325477B1 (en) Novel tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
AU2016243939B2 (en) Heterocyclic compounds as LSD1 inhibitors
US10125133B2 (en) Substituted [1,2,4]triazolo[1,5-a]pyridines and substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors
ES2708224T3 (es) 4-Imidazopiridazín-1-il-benzamidas y 4-imidazotriazín-1-il-benzamidas como inhibidores de Btk
ES2590508T3 (es) Purinas macrocíclicas para el tratamiento de infecciones víricas
ES2672530T3 (es) Amidas heterocíclicas como inhibidores de cinasas
EP2776439B1 (en) Purine derivatives for the treatment of viral infections
AU2020281180A1 (en) Pyrimidine derivatives for the treatment of viral infections
ES2532402T3 (es) Métodos de preparación de derivados de quinazolinona
ES2696526T3 (es) Crystal forms of 5-chloro-N2- (2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl) -N4- [2- (propan-2-sulfonyl) -phenyl] -pyrimidin-2,4 -diamine
NL1025414C2 (nl) Bereiding van gesubstitueerde chinazolinen.
JP6523566B2 (ja) ジヒドロピリド環化合物の結晶形、製造方法および中間体
EP3070089B1 (en) Aminomethyl tryptanthrin derivative, preparation method and application thereof
WO2015081203A1 (en) Bicyclic heterocycles as bet protein inhibitors
CA2882786C (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases.
ES2665419T3 (es) 1,2,5-Oxadiazoles como inhibidores de la indoleamina 2,3-dioxigenasa
US4923986A (en) Derivatives of physiologically active substance K-252
TW553939B (en) Processes and intermediates for preparing N-ethynylphenyl-4-quinazolinamine anti-cancer compounds
US9216989B2 (en) (Poly) aminoacetamide derivatives of epipodophyllotoxin their process of preparation and their applications in therapeutics as anticancer agents
ES2765819T3 (es) Micro-RNA inhibitor
CN105153122B (zh) [(吲哚-3-基)嘧啶-2-基]氨基苯基丙-2-烯酰胺衍生物及盐、制备方法、应用
ES2618007T3 (es) New pyrrolopyrimidine compounds as protein kinase inhibitors
JP6250564B2 (ja) チエノピリミジン誘導体の製造方法
CA2929661A1 (en) Deuterated diaminopyrimidine compounds and pharmaceutical compositions comprising such compounds

Legal Events

Date Code Title Description
PB01 Publication
C06 Publication
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20201010

Address after: No.21, Yangwan street, Yijin Town, Zongyang County, Tongling City, Anhui Province

Patentee after: Tongling wangyantang Biotechnology Co., Ltd

Address before: 215000 Jiangsu Province, Suzhou City Industrial Park Commercial Plaza Building 1 room 1305 Lianfeng

Patentee before: SUZHOU MIRACPHARMA TECHNOLOGY Co.,Ltd.

TR01 Transfer of patent right